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The outlook on stem cell (SC) biology is shifting from a rigid hierarchical to a more
ﬂexible model in which the identity and the behavior of adult SCs, far from being ﬁxed,
are determined by the dynamic integration of cell autonomous and non-autonomous
mechanisms. Within this framework, the recent discovery of thousands of non-coding
RNAs (ncRNAs) with regulatory function is redeﬁning the landscape of transcriptome
regulation, highlighting the interplay of epigenetic, transcriptional, and post-transcriptional
mechanisms in the speciﬁcation of cell fate and in the regulation of developmental
processes. Furthermore, the expression of ncRNAs is often tissue- or even cell type-
speciﬁc, emphasizing their involvement in deﬁning space, time and developmental stages
in gene regulation. Such a role of ncRNAs has been investigated in embryonic and induced
pluripotent SCs, and in numerous types of adult SCs and progenitors, including those
of the breast, which will be the topic of this review. We will focus on ncRNAs with an
important role in breast cancer, in particular in mammary cancer SCs and progenitors, and
highlight the ncRNA-based circuitries whose subversion alters a number of the epigenetic,
transcriptional, and post-transcriptional events that control “stemness” in the physiological
setting.
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BIOGENESIS AND FUNCTIONS OF miRNAs AND lncRNAs
The “non-coding revolution” has completely shifted our view of
gene expression programs, which have historically been based
on the assumption that only protein coding genes could specify
cellular functions. Recent research has highlighted the exis-
tence of numerous species of non-coding RNAs (ncRNAs) and
provided compelling evidence of a signiﬁcant regulatory role
of these molecules, impacting both on physiology and disease
(Ambros, 2004; Bushati and Cohen, 2007; Gangaraju and Lin,
2009; Mercer et al., 2009; Ponting et al., 2009; Wilusz et al., 2009;
Berezikov, 2011; Lujambio and Lowe, 2012). Indeed, the num-
ber of ncRNAs per genome correlates far better with organism
complexity than the number of coding genes, suggesting that
RNA-based regulatory mechanisms are critical in the evolution
of developmental complexity (Taft et al., 2007).
Regulatory ncRNAs can be divided into two classes based on
their length: small and long ncRNAs (lncRNAs). Small ncRNAs
comprise the short (<200 nt) RNA species, such as small-
interfering RNAs (siRNAs, 19–23 nt), piwi-interacting RNAs
(piRNAs, 26–30 nt), and microRNAs (miRNAs, 18–25 nt). lncR-
NAs comprise different types of transcripts, 100s to 1000s of
nucleotides long, which are usually classiﬁed according to their
genomic localization relative to the protein coding genes: sense,
antisense, intronic, and intergenic ncRNAs.
miRNAs: BIOGENESIS AND FUNCTIONS
Since the discovery in 1993 of the ﬁrst small regulatory RNAs, lin-4
and let-7, which control the timing of C. Elegans larval develop-
ment (Lee et al., 1993; Reinhart et al., 2000), thousands of different
miRNAs have been identiﬁed in different organisms, includ-
ing plants, animals and viruses (Lagos-Quintana et al., 2001).
According to the last release of the miRNA database (miRBase
http://www.mirbase.org – release 21) 1881 precursor and 2588
mature miRNAs exist in the human genome (Kozomara and
Grifﬁths-Jones, 2014).
The biogenesis of miRNAs is a multistep process (reviewed
in Ha and Kim, 2014 and summarized in Figure 1). The
canonical pathway consists of at least four steps: transcrip-
tion, nuclear, and cytoplasmic processing, loading into RNA-
induced silencing complex (RISC) and decay. Transcription
of miRNAs usually involves RNA polymerase II (Pol II),
meaning that miRNA genes share the transcriptional machin-
ery of protein coding genes, including transcription factors,
enhancers, and epigenetic regulation. The genomic organi-
zation of miRNA genes also inﬂuences their transcription.
Intragenic miRNAs, which constitute ∼40–45% of all human
miRNAs, are co-transcribed with their “host gene” and, thus,
share the same transcriptional regulation. Conversely, inter-
genic miRNAs form independent transcriptional units (Garzon
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FIGURE 1 | Genome organization and biogenesis of microRNAs
(miRNAs). miRNA genes are interspersed in the genome with various
possible locations as depicted on top. The ﬁgure summarizes the steps of the
canonical miRNA biogenetic pathway, including the production of a primary
transcript (pri-miRNA) by RNA polymerase II or III (Pol II or III), nuclear and
cytoplasmic processing, loading into the miRISC complex, and the
degradation of mature miRNAs. The function of miRNAs is exerted in the
cytosol at the level of the miRISC, where miRNAs induce target gene
repression by various mechanisms, including inhibition of protein synthesis
and mRNA destabilization.
et al., 2009). Occasionally, multiple miRNAs are organized in a
single transcriptional unit, named “miRNA cluster” (Lee et al.,
2002).
The expression of miRNAs begins with a long primary tran-
script, called the primary miRNA (or “pri-miRNA”), which
contains a stem-loop region for each encoded miRNA and can
range in size from hundreds of nucleotides to 10s of kilobases.
Two processing events are required to generate the mature miRNA
duplex, each generating an RNA molecule with a 5′ phosphate
and a ∼2 nt 3′ overhang (Han et al., 2006). The ﬁrst occurs
in the nucleus and is mediated by the Microprocessor com-
plex, composed of the RNase III endonuclease DROSHA and
the DiGeorge syndrome Critical Region 8 (DGCR8) protein,
which recognizes dsRNA–ssRNA junction and directs the cleav-
age site 11 nt away (Denli et al., 2004; Gregory et al., 2004).
This cleavage event produces an intermediate hairpin precur-
sor molecule of ∼65–100 nt, called the “pre-miRNA,” which is
translocated from the nucleus to the cytoplasm by Exportin 5
and RAN–GTP (Lund et al., 2004). The second processing event
occurs in the cytosol and is mediated by the RNase III endonu-
clease DICER in complex with the TAR RNA Binding Protein
(TRBP; Bernstein et al., 2001). This last cleavage event gener-
ates the mature miRNA:miRNA∗ duplex (18–24 nt in length),
which is immediately incorporated into the RISC, composed of
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Argonaute (AGO) proteins (Hammond et al., 2001; Mourelatos
et al., 2002). However, only one strand of the duplex is retained
in the RISC (the “guide” miRNA), while the other is discarded
and degraded, resulting in a strong bias for guide strands in the
miRNA pool (Khvorova et al., 2003; Schwarz et al., 2003). This
miRNA maturation process is mainly regulated at the level of
nuclear processing, and sequence determinants and auxiliary fac-
tors also contribute to its regulation (Auyeung et al., 2013; Mori
et al., 2014).
There is evidence that a small proportion of miRNAs (<1%)
are produced by non-canonical mechanisms, including: Drosha-
independent mechanisms (as in the case of “mirtrons”), in which
mRNA splicing produces a small RNA hairpin thereby bypassing
Drosha processing (Berezikov et al., 2007); andDicer-independent
mechanisms (as in the case of miR-451), in which a short stem-
loop is not loaded onto Dicer but directly processed byAgo2 (Yang
et al., 2010).
Once loaded into the AGO-based complexes, miRNAs appear
as rather stable molecules with long half lives (greater than
24 h); however, scattered reports suggest that miRNAs could also
undergo a rapid and regulated decay (Krol et al., 2010; Rissland
et al., 2011; Ruegger and Grosshans, 2012). Although miRNA bio-
genesis has been studied for 20 years, the mechanisms of miRNA
degradation are largely obscure, in particular in higher organ-
isms. At least two possible mechanisms have been proposed. The
ﬁrst involves the enzymatic activity of speciﬁc nucleases (“miR-
Nases”), such as the plant SNDs (Wu and Belasco, 2008) and the
worm 5′-to-3′ exoribonucleases XRN1 and XRN2 (Chatterjee and
Grosshans, 2009). The second is a target-dependent mechanism,
in which miRNA turnover is mediated by the interaction with
mRNA targets that promote miRNA unloading from AGO and
degradation (Baccarini et al., 2011; Ruegger and Grosshans, 2012;
De et al., 2013).
Typically, miRNAs exert speciﬁc biological actions by interfer-
ing with a key regulator (e.g., a transcription factor) responsible
for a deﬁned phenotype (the “hub target”mechanism) or through
the coordinated action on multiple target genes that belong to the
same pathway (the “multiple targets” mechanism; Hausser and
Zavolan,2014). The interaction betweenmiRNAs and theirmRNA
targets occurs in the cytosol at the level of the RISC and is directed
by Watson–Crick base-pairing with the “miRNA Responsive Ele-
ment” (MRE), usually located in the 3′-Untranslated Region
(3′-UTR) of the target mRNA (Bartel, 2009). The critical deter-
minant of miRNA speciﬁcity is a region located at the 5′ end of
the miRNA in positions 2–8, called the “seed” sequence, which
deﬁnes the target speciﬁcity of any mature miRNA. As the extent
of miRNA:mRNA interaction is limited, 100s or even thousands
of different genes are potential miRNA targets. These targets can
be partially inferred with prediction algorithms that search in
the 3′UTR of protein coding genes for the presence of MREs
(i.e., miRanda, Targetscan, Pictar, DIANA microT, and RNAhy-
brid; Thomas et al., 2010). However, none of these algorithms
are completely accurate, especially as some miRNA targets rely on
“seedless” interactions.
Target down-modulation occurs through multiple mecha-
nisms, including translational repression (inhibition of cap recog-
nition or 60S recruitment, ribosome drop-off, and increase of
termination efﬁciency) and/or mRNA destabilization (deadeny-
lation or decapping). Rarely, in cases of perfect or near-perfect
complementarity, miRNAs can function as siRNAs, inducing
mRNA degradation (Carthew and Sontheimer, 2009).
lncRNAs: BIOGENESIS AND FUNCTIONS
Long ncRNAs consist of a heterogeneous class of ncRNAs, oper-
ationally deﬁned as any RNA molecule with low coding potential
and a size greater than 200 nt: a cut-off arbitrarily based on
RNA puriﬁcation protocols (Kapranov et al., 2007). They can
be classiﬁed, according to their genomic organization relative to
protein-coding transcripts (Rinn andChang,2012), as: (i) overlap-
ping transcripts (sense or antisense, promoter-/intronic-/3′UTR-
associated); (ii) divergent transcripts, which share the same
promoter with coding genes, but are transcribed in the oppo-
site direction; (iii) intergenic transcripts (lincRNAs), which are
located in gene-desert regions (see Figure 2).
Genetic loci of lncRNAs are similar to those of mRNAs, shar-
ing the same transcriptional machinery (Pol II), same layers of
epigenetic regulation (such as histone-modiﬁcation proﬁles) and
splicing signals (Guttman et al., 2009; Derrien et al., 2012). Almost
half of the lncRNAs are also capped and polyadenylated. LncR-
NAs are frequently bi-exonic and localize predominantly in the
nucleus. Their expression is highly cell-type speciﬁc, but on aver-
age to a lesser extent than protein-coding genes (Ravasi et al., 2006;
Cabili et al., 2011; Djebali et al., 2012). Although most lncRNAs
have very low translational potential, ribosome proﬁling (a tech-
nique that uses deep sequencing of ribosome-protected fragments
to monitor in vivo translation) revealed that many lncRNAs can be
engaged by ribosomes, and some have the potential of producing
small peptides (<100 amino acids), whose biological signiﬁcance
is completely unknown (Ingolia et al., 2011; Bazzini et al., 2014).
Identiﬁcation of lncRNAs is not a trivial task, but requires unbi-
ased RNA detection methods, precise mapping in the genome
within regions distinct from those occupied by coding transcripts,
and analysis of protein-coding potential. Current approaches
applied to lncRNA identiﬁcation include: (i) tiling microar-
rays; (ii) unbiased RNA cloning techniques (SAGE and CAGE);
(iii) massive parallel sequencing of transcripts (RNA-sequencing,
RNA-seq); and (iv) chromatin immunoprecipitation combined
with DNA sequencing (ChIP-seq). The latter approach is based
on the identiﬁcation of chromatin domains associated with
active transcription, such as those with histone H3 lysine 4
trimethylation (H3K4me3) at the promoter, and histone H3
lysine 36 trimethylation (H3K36me3) on the transcribed gene
body [known as “H3 K4-K63 domains,” (Mikkelsen et al., 2007;
Guttman et al., 2009)]. Mapping in the genome is easier for
lncRNAs that are located in gene-desert regions (intergenic – lin-
cRNAs), while strand-speciﬁc reactions (strand-speciﬁc RT-qPCR
or sequencing) are needed to identify overlapping lncRNAs. The
coding potential of lncRNAs is typically assessed by searching
for any open reading frame (ORF) that match known pro-
teins or domains. However, this approach could miss small
ORFs or newly evolved proteins. Alternatively, methods that use
the codon substitution frequency to determine the likelihood
that a sequence is protein coding can be exploited (Lin et al.,
2011).
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FIGURE 2 | Genomic organization and functions of long ncRNAs
(lncRNAs). lncRNA genes are interspersed in the genome in various
possible locations in relation to protein coding transcripts, such as (i)
overlapping; (ii) intergenic; or (iii) divergent transcripts. Transcription of
lncRNAs follows the same rules as for protein coding genes and is
executed by RNA Pol II. Genomic features associated with transcription
[such as CpG island (green boxes) or histone marks (histone H3
“K4K36 domains”)] provide a useful strategy to identify expressed
lncRNAs. Functions of lncRNAs are executed by multiple modes of
action and can occur both in the nucleus and in the cytosol. The ﬁgure
shows some examples of nuclear or cytoplasmic functions of some
known lncRNAs.
In contrast to miRNAs, which are highly conserved and
mainly involved in negative regulation of gene expression at the
post-transcriptional level, lncRNAs are poorly conserved and
could regulate gene expression (either positively or negatively)
at numerous levels by a variety of mechanisms (summarized in
Figure 2), some of which are yet to be characterized (Cech and
Steitz, 2014). Expression of lncRNAs occurs at a very precise
time and/or developmental stage, suggesting a general role as
“molecular signals” that integrate developmental cues or respond
to different stimuli (Wang and Chang, 2011). Due to their
purely transcriptional nature, lncRNAs could function immedi-
ately after transcription (with no need for protein translation)
and act either locally, by affecting the expression of neighbor-
ing genes (cis-acting), such as during imprinting, or at distant
sites (trans-acting ; Ebisuya et al., 2008; Guttman and Rinn, 2012).
Even in the absence of a regulatory function, the transcription
of lncRNAs could serve as a signal per se, interfering or fos-
tering the expression of neighboring/overlapping genes, as in
the case of the lncRNAs, AIR, and XIST (Rinn and Chang,
2012).
The regulatory function of lncRNAs could also depend on their
interaction with other molecules. In this case, lncRNAs act as
“decoys” that titrate away transcription factors, splicing proteins
or even miRNAs, thus relieving the activation/inhibition on tar-
get genes. Examples of such lncRNAs include TERRA, PANDA,
PTENP, linc-MD1, and linc-ATB. Alternatively, lncRNAs could
function as a “guide,” directing ribonucleoproteic complexes to
speciﬁc loci to control gene expression locally (on neighbor-
ing genes) or at distant sites. Lastly, lncRNAs could function
as scaffolds (e.g., HOTAIR – HOX antisense intergenic RNA),
upon which other molecular components are assembled, bring-
ing together independent functions/activities (Mercer et al., 2009;
Ponting et al., 2009; Wang and Chang, 2011).
NORMAL AND CANCER MAMMARY STEM CELLS
THE STEM CELL COMPARTMENT IN THE NORMAL MAMMARY GLAND
The mammary gland is a glandular epithelium composed of
milk-secreting hollow cavities, named alveoli, joined together by
ducts to form groups termed lobules. Ducts also connect differ-
ent lobules and eventually merge into the lactiferous duct that
opens into the nipple. Mature cells that compose the mam-
mary epithelium include luminal cells, in the inner layer of
the mammary gland, and myoepithelial cells, located in the
outer layer of the gland. The latter cells make contact with the
basement membrane, physically sustaining the organ and pro-
viding the contractile force needed during lactation (Figure 3).
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FIGURE 3 | Hierarchical organization of the mammary gland and breast cancer subtypes.The ﬁgure depicts the epithelial components of the mammary
gland. In the lower part, the characteristics of normal and cancer stem cells are summarized. (SC, stem cells; PC, progenitors; DC, differentiated cells).
The mammary gland is a highly dynamic organ that undergoes
important morphogenetic changes during adult development
(puberty) or during pregnancy-lactation and involution (Visvader
and Stingl, 2014). Remarkably, the mammary gland main-
tains the ability to perform structural remodeling for several
cycles, suggesting the existence of a reservoir of adult stem cells
(SCs) able to sustain multiple rounds of pregnancy-lactation-
involution and to generate all the cellular lineages that compose
the gland.
Pioneering experiments inmice, using transplantation of entire
sections of the gland (Deome et al., 1959) or isolated epithelial cells
(Stingl et al., 2006), proved the existence of a multipotent popu-
lation of rare cells able to reconstitute the entire organ: normal
mammary stem cells (MaSCs). This in vivo reconstitution assay
has become the gold standard in MaSC identiﬁcation (Shackle-
ton et al., 2006; Stingl et al., 2006; Cicalese et al., 2009) and has
allowed the evaluation of mammary repopulating units (MRUs,
functionally synonymous with MaSCs) in deﬁned cellular sub-
sets transplanted at limiting dilution, as a quantitative measure
of MaSC abundance (Visvader, 2009). Lineage tracing experi-
ments and reporter genes have helped to verify the clonality of
mammary outgrowths, suggesting that unipotent and multipo-
tent MaSCs coexist, endowed with the ability to repopulate the
mammary gland by generating the different luminal and basal
mammary lineages (Kordon and Smith, 1998; Van Keymeulen
et al., 2011; Rios et al., 2014; Wang et al., 2014). Similarly to most
adult SCs, MaSCs possess a number of deﬁning characteristics:
(i) multi-lineage differentiation potential (they can generate both
luminal and basal lineages); (ii) ability to self-renew, usually
through an asymmetric type of cell division, which generates one
daughter SC and one progenitor, and maintains homeostasis of
the SC pool; (iii) quiescence (or slow rate of division), unless
activated, as occurs during pregnancy or lactation; and (iv) abil-
ity to withstand anoikis, surviving in anchorage-independent
conditions.
An important advance in MaSC biology derived from the
work of Dontu et al. (2003), who developed an in vitro method-
ology, the mammosphere assay, which maintains MaSCs in an
undifferentiated condition and facilitates the study of self-renewal
mechanisms. The assay exploits the ability of SCs to grow in
anchorage independent conditions as clonal spheroids, com-
posed of quiescent SCs, progenitors and somewhat differentiated
cells. Under these culture conditions, MaSCs maintain their
fundamental properties (self-renewal and multilineage differenti-
ation potential) and can recapitulate mammary outgrowths when
transplanted in vivo (Dontu et al., 2003).
BREAST CANCER AND MAMMARY CANCER STEM CELLS
Breast cancer is themain disease of themammary gland and one of
the most common life-threatening diseases for women in Western
countries (DeSantis et al., 2014). Thanks to the advent of genome-
wide approaches, both oncologists andbiologists have realized that
breast cancer is a quite heterogeneous disease, and have attempted
to classify tumors according to theirmolecular characteristics. This
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has led to a classiﬁcation of breast tumors into at least ﬁve different
molecular subtypes, based on their peculiar transcriptional pro-
ﬁle: Luminal A, Luminal B, Her2-positive, Claudin-low, and Basal
tumors (Perou et al., 2000; Sorlie et al., 2001; Sotiriou et al., 2003;
Lehmann et al., 2011; Prat and Perou, 2011). These ﬁndings have
revealed the molecular basis for breast tumor heterogeneity and
suggested that different subtypes should be treated as different dis-
eases, with tailored treatments and therapeutic strategies (Sotiriou
and Pusztai, 2009).
As morphogenesis and homeostasis of adult tissues are sus-
tained by SCs, it has been hypothesized that a similar mechanism
might fuel the growth of tumors, relying on the existence of sub-
populations of cancer cells with stem-like properties (cancer stem
cells – CSCs, Medema, 2013). The CSC hypothesis implies that
tumors are hierarchically organized like normal tissues, with a
subset of tumor cells at the top of the hierarchy possessing the
ability to self-renew and to differentiate, albeit aberrantly. Breast
cancer was one of the ﬁrst solid malignancies in which CSCs were
identiﬁed and characterized, mostly immunophenotypically as
lin−/CD44+/CD24− cells (Al-Hajj, 2003). Mammary CSCs were
the only cells able to sustain tumor growth in NOD/SCID mice,
whereas cells that did not express the CSC markers were non-
tumorigenic (Al-Hajj, 2003). Mammary CSCs are also considered
to be responsible for relapse and metastasis. This contention is
based on multiple observations: (i) poorly differentiated, more
aggressive breast cancers tend to be CSC-rich, compared to more
highly differentiated, less aggressive, CSC-poor breast tumors
(Pece et al., 2010); (ii) mammary CSCs are relatively resistant to
both radiation treatments and cytotoxic chemotherapy in vitro
and in vivo (Liu and Wicha, 2010), a property reminiscent of
the intrinsic ability of MaSCs to withstand genotoxic stress; and,
ﬁnally, (iii) the proportion of cells with CSC properties is typically
increased after conventional therapies (Li et al., 2008; Creighton
et al., 2009).
Recent research has provided evidence of functional plastic-
ity within the SC compartment, suggesting that CSCs should
not be considered as a ﬁxed entity, solely derived from the
transformation of a normal SC, but rather as the result of the
acquisition of “stemness” properties by tumor cells (Gupta et al.,
2011). In particular, in cancer cell populations’ bidirectional
interconversion between CSCs and non-CSCs occurs under cer-
tain conditions (Roesch et al., 2010; Chaffer et al., 2011; Gupta
et al., 2011). This plasticity is not a universal property of can-
cer cells and it is appears to be associated with certain tumor
subtypes, such as breast basal carcinomas. Although it is cur-
rently unclear how frequently the interconversion between CSCs
and non-CSCs occurs in vivo, cell state dynamics are depen-
dent on external (i.e., microenvironment) and internal (i.e.,
genetic) cues, and rely on the same epigenetic, transcriptional
and post-transcriptional mechanisms that control “stemness” in
normal SCs (Roesch et al., 2010; Chaffer et al., 2011; Gupta et al.,
2011).
One such mechanism is the epithelial-to-mesenchymal tran-
sition (EMT), a reversible transcriptional program that is phys-
iologically activated during embryogenesis, allowing partial or
complete transition of cells from an epithelial to a mesenchymal
state (Thiery et al., 2009). Pathways leading to EMT are activated
by speciﬁc stimuli, such as transforming growth factor beta (TGF-
β) or ﬁbroblast growth factor (FGF), through the stimulation of
EMT transcription factors (EMT-TFs), such as members of the
snail family (SNAIL1/2), bHLH family (TWIST), and ZFH fam-
ily (ZEB1 and ZEB2), which repress epithelial gene expression
and foster the establishment of a motile and invasive mesenchy-
mal phenotype (Thiery and Sleeman, 2006). EMT program(s)
have been frequently associated with cancer progression, metasta-
sis and acquisition of SC-traits (Thiery et al., 2009; Hanahan and
Weinberg, 2011). In breast cells, the expression of EMT-TFs, such
as TWIST and SNAIL, induces mesenchymal and stem-related
markers, increases mammosphere formation, expands the CSC
population (CD44+/CD24−) and induces tumorigenesis (Mani
et al., 2008).
Of note, bothmouse (CD49fhigh/CD24med) and humanMaSCs
(CD44high/CD24low) express markers associated with EMT, such
asN-cadherin,Vimentin, SNAIL1/2, and SLUG(Mani et al., 2008).
Inmousemodels, the expressionof the EMT–TFSLUG is sufﬁcient
to reprogram luminal progenitor cells (CD61+) to fully functional
MaSCs suggesting that a certain degree of plasticity between SC
and progenitor states also exists in the normal breast epithelium
(Guo et al., 2012). Indeed, interconversion from an epithelial to
a mesenchymal/stem-like state has been also observed in human
mammary epithelial cells (Chaffer et al., 2011, 2013). In this con-
text, the maintenance of self-renewal properties and protection
from spontaneous differentiation is achieved through autocrine
and paracrine signals, which involves TGF-β canonical and non-
canonical Wnt pathway activation and EMT-TFs (SLUG, TWIST,
ZEB1/2; Scheel et al., 2011).
Finally, and of relevance to the subject of this review, sev-
eral ncRNAs have been associated with EMT in the breast gland,
frequently acting together, in concert with chromatin regulators
(CRs) and TFs. Relevant examples are miRNAs of the miR-200
family, miR-205, miR-7, miR-22, and some lncRNAs, including
HOTAIR, linc-RoR, H19, and lncRNA-ATB (discussed below).
CELL FATE SPECIFICATION BY miRNAs AND lncRNAs
OCCURS BY INTEGRATING MULTIPLE SIGNALING
PATHWAYS INVOLVED IN SC AND CSC BIOLOGY
As previouslymentioned, the activity of ncRNAs, eithermiRNAor
lncRNAs, is integrated with signaling networks and the transcrip-
tional framework, thus, generating complex circuits that control
cell fate and differentiation. Hereafter, we will discuss the cur-
rent knowledge of the involvement of ncRNAs in the biology of
MaSCs and of mammary CSCs (summarized in Tables 1 and 2,
and schematized in Figure 4).
LET-7 FAMILY AND IL6/STAT3 CIRCUITRY
Theﬁrst report showing the involvement of amiRNA inmammary
CSCs was in 2007, when Yu et al. (2007) described their observa-
tion that let-7 levels were markedly reduced in tumor-initiating
cells (TICs, deﬁned as lin−/CD44+/CD24−, and operationally
equal to CSCs) compared to their non tumorigenic counterparts.
To identify miRNAs potentially involved in the control of CSC
biology, they used a derivative of the SK-BR-3 breast cancer cell
line, named SK-3rd, obtained by serial passaging of the origi-
nal cell line in NOD/SCID mice treated with chemotherapy. As
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Table 1 | List of microRNAs (miRNAs) and long ncRNAs (lncRNAs) associated with normal breast stem cells (SCs).
ncRNAs CellType Function Signaling
upstream
Signaling
downstream
Target genes Reference
Let-7 Normal breast cells
(MCF10A)
Human
Inhibition of
self-renewal/promoter
of differentiation
SRC/IL-6/NF-kB LIN28/Let-
7/STAT3
Iliopoulos et al. (2009)
Let-7/miR-
205/miR-22
Mammary gland
progenitors
(Comma-Dβ) Mouse
Inhibition of
self-renewal by let-7
Ibarra et al. (2007)
miR-205 Breast epithelial cells
(HMEC)
Human
Inhibition of EMT JAG1/NOTCH2 Hes1/ZEB1 ZEB1/NOTCH2 Chao et al. (2014)
miR-200c Human primary
breast SCs
(CD44+/CD24−)
Inhibition of
self-renewal
BMI/PRC1 Shimono et al. (2009)
miR-200c Human normal breast
cell lines (MCF12A –
HMEC)
Inhibition of
EMT/stemness
p53 ZEB1/BMI-1 Chang et al. (2011)
miR-22 Normal breast cells
(MCF10A – HMEC)
and Mouse models
Promoter of EMT and
stemness
ZEB1–ZEB2 TET and miR-200
inhibition
Song et al. (2013)
miR-205/-200
family
MDCK cells Maintenance of the
epithelial state
TGF- β ZEB1–ZEB2 Gregory et al. (2008)
The table summarizes the miRNAs and the lncRNAs linked to stem cells or progenitors of the mammary gland, cited in the text. Shown are: the cell type or tumor
type (source) in which the miRNA/lncRNA has been investigated, the function in that compartment, the upstream and downstream signaling, the target genes, and
the appropriate references.
chemotherapy typically increases the proportion of CSCs within
breast tumors, the SK-3rd derivative had an increased proportion
of CSCs compared with the parental line, as assessed by the mam-
mosphere assay, cell surface marker expression (CD44+/CD24−)
and in vivo xenotransplantation assays. Several members of the
let-7 family (plus other miRNAs, such as the miR-200 family)
were depleted in SK-3rd cells as compared to the parental cells.
Importantly, the same miRNAs were downregulated in CSCs from
clinical breast cancer samples (lin−/CD44+/CD24−) compared to
their non-tumorigenic counterparts. The overexpression of let-7
in mammary CSCs caused a striking impairment in prolifera-
tion, mammosphere-forming ability, and tumor formation and
metastasis in vivo. Mechanistically, the levels of let-7 inversely
correlated with those of two of its direct targets, H-RAS and
HMGA2, which are involved in SC self-renewal and multipo-
tency regulation. Silencing of these two targets in mammary CSCs
partially recapitulated the effects of let-7 overexpression, suggest-
ing that the repression of ‘stemness’ traits by let-7 is, in part,
mediated by the repression of H-RAS and HMGA2 (Yu et al.,
2007).
In the mouse, members of the let-7 family were shown to be
expressed at low levels in self-renewing progenitors (ALDH+/Sca-
1+) and induced upon differentiation, suggesting that low levels
of let-7 mark the self-renewal compartment and could be used
to prospectively isolate MaSCs (Ibarra et al., 2007). Accordingly,
the let-7 family emerged as the most induced group of miR-
NAs upon estradiol treatment in human luminal cells (MCF-7;
Bhat-Nakshatri et al., 2009).
Several independent studies further suggested that miRNAs of
this family are implicated in the self-renewal of CSCs in breast and
other cancers, by multiple mechanisms. One of these mechanisms
involves the pluripotency gene known as LIN28/LIN28B, which
inhibits the function of let-7 by interfering with its biogene-
sis (Piskounova et al., 2011). LIN28 is frequently overexpressed
and associated with advanced malignancy in multiple cancer
types (Viswanathan et al., 2009). In breast cancer, LIN28 expres-
sion confers CSC-traits and impinges on signaling mechanisms
involved in self-renewal of normal and cancer SCs, such as
the Wnt/beta-catenin pathway, NF-kB signaling, and inﬂam-
matory cytokine signaling (Iliopoulos et al., 2009; Cai et al.,
2013). Members of the interleukin-6 (IL-6) family, which are
induced in a paracrine/autocrine fashion in breast cancer, medi-
ate the activation of the Janus Kinase 2 (JAK2) and of the
signal-transducer and transcription factor 3 (STAT3) promot-
ing the expansion of mammary CSCs (Marotta et al., 2011; Yu
et al., 2014). The IL-6/STAT3 axis can induce LIN28 expres-
sion, which in turn inhibits let-7 activity, thus generating a
positive feedback loop (let-7 targets IL-6) that confers SC traits
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Table 2 | List of miRNAs and lncRNAs associated with breast cancer stem cells (CSCs).
ncRNAs Source Function Signaling
upstream
Signaling
downstream
Target genes Reference
Let-7 lin/CD44+/CD24−
(SK-3rd)
Human
Inhibition of
self-renewal
H-RAS and
HMGA2
Yu et al. (2007)
Let-7 Human breast cells
transformed with Src
(MCF10A ER-SRC)
Inhibition of cell
transformation
SRC/IL-6/NF-kB LIN28/Let-
7/STAT3
Iliopoulos et al. (2009)
Let-7 TN and HER2 breast
cancers
Human
Inhibition of CSC
maintenance
SHP2 MAPK/ERK and
MYC
RAS/MYC Aceto et al. (2012)
Let-7/miR-200
families
Breast cancer cells
(MCF7)
Human
Inhibition of EMT JAK2/STAT3 LIN28/Let-7
and
miR-200/ZEB1
HMGA2/ZEB1 Guo et al. (2013)
miR-205/-200
family
Human primary breast
cancers/ MDCK cells
Maintenance of the
epithelial state/tumor
suppression
TGF -β ZEB1–ZEB2 Gregory et al. (2008)
miR-205 Breast cancer cells
MDA-MB-231 – BT459
– PT
Human
Inhibition of EMT and
mammary
tumorigenesis
JAG1/NOTCH2 Hes1/ZEB1 ZEB1/NOTCH2 Chao et al. (2014)
miR-200c Human primary BCSCs
(CD44+/CD24−)
Inhibition of
self-renewal
BMI/PRC1 Shimono et al. (2009)
miR-200b Human CD44+/CD24−
from MCF10A-SRC
Inhibition of
self-renewal/invasion
and tumor growth
SUZ12/PRC2 and
E-cadherin
Iliopoulos et al. (2010)
miR-200b/-
200c
Multiple human breast
cancer cells
Interconversion of
CSCs to non-CSCs
TGF -β ZEB1 Chaffer et al. (2013)
miR-200c/-141 Human cancer cells
(MDA-MB-231)
Inhibition of
EMT/stemness/survival
Jag1/Maml2/3/
ZEB1
Brabletz et al. (2011)
miR-200c Human breast cancer
cell lines BT549
Inhibition of
EMT/stemness
p53 ZEB1/BMI-1 Chang et al. (2011)
miR-22 Human breast cancer
and Mouse models
Promoter of
metastasis, EMT,
invasiveness and
stemness
ZEB1–ZEB2 TET and miR-200
inhibition
Song et al. (2013)
HOTAIR Human breast cancer
cells (MCF -7;
MCF-10A; SK-BR3;
MDA-MB-231)
Promoter of tumor
metastasis and
invasion
Metastasis
suppressor
genes
PRC2 and
chromatin state
of several genes
Gupta et al. (2010)
HOTAIR/miR-7 Breast cancer cell lines
(MCF -7; MDA-MB-231)
Promoter/Inhibitor
(HOTAIR/miR-7) of
EMT/stemness
STAT3 miR-7:SETDB1
HOTAIR:HoxD10
Zhang et al. (2014).
Linc-ROR iPSCs/ES cells Maintenance of
self-renewal
Sox2, Nanog,
Oct4
Self-renewal
genes
Sponge for
miR-145 family
Wang et al. (2013b)
(Continued)
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Table 2 | Continued
ncRNAs Source Function Signaling
upstream
Signaling
downstream
Target genes Reference
Linc-ROR Multiple human
breast cancer cells
Promoter of
EMT/stem-like
features
Sponge for
miR-205
Hou et al. (2014)
Lnc-H19 Muscle cells and
cancer cells
Promoter of muscle
differentiation
Differentiation
genes/let-7
targets
Sponge for let-7
family
Kallen et al. (2013)
Lnc-H19/miR-675 Human breast cancer
and cell lines
(MDA-MB-468)
EMT/promoter of
tumor metastasis
TGF -β
hypoxia/HGF
/SF
PI3K/AKT/Slug E-cadherin Matouk et al. (2007)
Lnc-ATB Hepatocellular
carcinomas and
Human Breast cancer
cells (MCF-7)
EMT/promoter of
tumor metastasis
TGF-β/IL-11 ZEB1–
ZEB2/STAT3
Sponge for
miR-200 family
Yuan et al. (2014)
The table summarizes the miRNAs and the lncRNAs, linked to breast cancer stem cells, cited in the text. Shown are: the cell type or tumor type (source) in which the
lncRNA has been investigated, the function in that compartment, the upstream and downstream signaling, the target genes and the appropriate references.
to mammary epithelial cells (Iliopoulos et al., 2009; Guo et al.,
2013).
A similar loop is also operational downstream of the
Src-homology 2 domain-containing phosphatase SHP2: a protein-
tyrosine phosphatase encoded by the PTPN11 locus. SHP2
is a transducer of RTK and cytokine-receptor signaling that
promotes breast cancer progression and a CSC-phenotype in
ER-negative cancers (Aceto et al., 2012). In this case, a signal-
ing cascade that involves the mitogen-activated protein kinase
(MAPK)/extracellular signal-related kinase (ERK) pathway and
the MYC-oncogene is activated by SHP2 and sustained through
let-7 downregulation. Indeed, let-7 targets multiple genes, includ-
ing RAS and MYC, which feedback on ERKs and LIN28, respec-
tively, thus creating a loop that maintains CSCs and fosters
metastasis in HER2+ and triple-negative breast cancers (Aceto
et al., 2012).
THE H19 lncRNA AND BREAST CANCER METASTASIS
Human H19 was the ﬁrst lncRNA with no coding potential
to be described, opening the door to the so-called “non-
coding revolution” (Brannan et al., 1990). The H19 gene belongs
to a conserved imprinted region on human chromosome 11,
located near the insulin-like growth factor 2 (IGF2) gene, and
encodes a 2.3 kb long, cytoplasmic, capped, and polyadenylated
ncRNA that functions primarily in the epigenetic silencing of
the IGF2 gene (Gabory et al., 2010). H19 is strongly induced
during embryogenesis and selectively expressed by the mater-
nally inherited chromosome, with the function of silencing in
cis the maternal IGF2 allele, thereby allowing selective expres-
sion of the paternal allele (Bartolomei et al., 1991; Gabory et al.,
2010).
In adult tissues, H19 expression is retained in muscles (skele-
tal muscles and the heart), or is suddenly activated in cancers,
where it is believed to act mainly as an oncogene (Matouk et al.,
2007; Gabory et al., 2010). H19 functions in the adult are linked to
miRNA circuits: H19 RNA is the precursor of miR-675, which is
encoded in its ﬁrst exon and involved in muscle development and
regulation of EMT (Cai and Cullen, 2007; Matouk et al., 2014).
Furthermore, H19 acts as a “decoy” for miRNAs of the let-7 family
during muscle differentiation (Kallen et al., 2013). By this mecha-
nism, the expression of H19 relieves the repression on endogenous
let-7 targets, such as HMGA2 and DICER, potentially contribut-
ing to the onset of the transformed phenotype (Kallen et al., 2013).
Indeed, H19 expression is high in some cancers, including breast
carcinomas, where it is associated with metastasis and the acquisi-
tion of EMT traits (Matouk et al., 2014). Several mechanisms can
induce H19 expression in breast cancer cells, including: (i) acti-
vation from within the cell by upregulation of E2F1 (Berteaux
et al., 2005), c-MYC (Barsyte-Lovejoy et al., 2006), or the loss of
the tumor suppressor p53 (Dugimont et al., 1998); or (ii) activa-
tion by external stimuli, such as TGF-β, hypoxia, and HGF/SF.
In this context, high levels of H19 could promote the loss of
E-cadherin and the upregulation of the EMT-inducer SLUG to
reinforce the mesenchymal state, through as yet an unknown
mechanism that implicates both miR-675 and let-7 (Matouk et al.,
2014).
THE miR-200 FAMILY IN BETWEEN EMT AND CHROMATIN REGULATION
In human primary samples, Shimono et al. (2009) identiﬁed a
signature of 37 miRNAs differentially expressed between mam-
maryCSCs and their non-tumorigenic counterparts. In particular,
severalmembers of themiR-200 family were found to be downreg-
ulated in mammary CSCs. This family comprises ﬁve members,
which are organized in two conserved genomic clusters, one
containing miR-200b, -200a, and -429 and the other encom-
passing miR-200c and miR-141 (Figure 4). miRNAs of this
family were also found to be downregulated in MaSCs isolated
by ﬂow cytometry (lin−/CD49fhigh/CD24med/CD29high) from the
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FIGURE 4 | microRNAs and lncRNAs control stemness and
differentiation by interacting with signaling and transcriptional/
epigenetic networks.The ﬁgure summarizes the activity of the main miRNAs
and lncRNAs involved in the control of normal or cancer mammary SCs
together with signaling networks (cytosol) and the transcriptional/epigenetic
framework (nucleus) to which they belong or that they regulate. Straight and
dashed arrows refer to direct or indirect interaction/regulation, respectively.
Red lines mark inhibitory interactions. The activity of transcriptional factors
(TFs) and chromatin regulators (CRs), cited in the text and involved in the
control of stemness and differentiation, are also shown.
normal mouse mammary gland. Forced expression of one mem-
ber of the family, miR-200c, repressed both normal mammary
outgrowths in mammary gland reconstitution assays, and the in
vivo tumorigenicity of human and mouse mammary CSCs. Mech-
anistically, this was linked to the ability of miR-200c to target BMI1
(B-lymphoma Mo-MLV insertion region 1 homolog), a compo-
nent of the Polycomb Repressing Complex 1 (PRC1) and a critical
regulator of SC self-renewal and differentiation (Shimono et al.,
2009).
In a different setting, members of the miR-200 fam-
ily were found to be downregulated in mammary CSCs
(CD44high/CD24low) isolated from MCF10A cells transformed
with the SRC oncogene (Iliopoulos et al., 2010). In this con-
text, miR-200(s) targets SUZ12, a component of the PRC2, which
epigenetically controls the expression of several genes, including
E-cadherin, by H3K27 trimethylation. The miR-200/SUZ12/E-
cadherin axis appeared to be important for the maintenance
of mammary CSCs and in the regulation of metastasis. Over-
expression of miR-200b or loss of SUZ12 expression inhibited
mammosphere formation, invasion, and tumor growth from
genetically distinct breast cancer cell lines, and cooperated with
chemotherapy to prevent tumor relapse in xenograft models
(Iliopoulos et al., 2010).
The notion of regulation of CSC traits bymiR-200 has been fur-
ther conﬁrmed in multiple models (Brabletz et al., 2011; Chang
et al., 2011; Chaffer et al., 2013; Lim et al., 2013; Song et al.,
2013), and tightly linked to the function of EMT–TFs of the
ZEB1/2 and to EMT (Christoffersen et al., 2007; Hurteau et al.,
2007; Burk et al., 2008; Gregory et al., 2008; Korpal et al., 2008;
Park et al., 2008; Scheel et al., 2011). Indeed, the expression of
miR-200 family members is highly enriched in epithelial cells,
almost absent in mesenchymal or basal cells, and positively cor-
relates with the epithelial marker E-cadherin (Park et al., 2008).
The E-box binding factors ZEB1 and ZEB2 possess a remark-
able number of conserved binding sites for miR-200 miRNAs.
A total of eight MREs are present in the 3′UTR of ZEB1 (5 for
miR-200bc/429, and 3 for miR-200a and -141) and nine in ZEB2
(six for miR-200bc and three more for miR-200a/-141) (Christof-
fersen et al., 2007; Figure 4). Conversely, miR-200 genetic loci
possess multiple binding site for ZEB1/2, generating a double
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negative feedback loop that controls the epithelial or mesenchy-
mal phenotype (Burk et al., 2008; Gregory et al., 2008; Korpal
et al., 2008). This “switch” mechanism is one of the most rep-
resentative examples of a transcriptional circuitry that regulates
cell fate. The two players, ZEB1/2 and miR-200, which regu-
late the mesenchymal and the epithelial fate, respectively, are
never in equilibrium: as one of the two starts accumulating the
other disappears, critically contributing to the establishment of
cell fate.
Studies from the Weinberg’s lab, suggested a role for the
ZEB1/miR-200 axis also in the regulation of cancer cell plasticity,
by integrating external stimuli from the microenvironment (such
as TGF-β) with epigenetic mechanisms (Chaffer et al., 2013). In
several breast cancer cell lines, CD44low (non-CSC) and CD44high
(CSCs) cells can interconvert into each other by regulating ZEB1
expression and, thus, miR-200 levels. Mechanistically, this occurs
through the epigenetic regulation of the ZEB1 promoter, which
converts from a poised state (with the coexistence of active and
inactive chromatin marks – such as H3K4me3 and H3K27me3) to
an active state (by removal of the repressing mark – H3K27me3)
in response to TGF-β signaling (Chaffer et al., 2013).
Finally, the ZEB1/miR-200 axis has been shown to interact with
other pathways associated with SC-biology, such as the Notch
pathway, by interfering with the ligand Jagged-1 (JAG1) and the
mastermind-like co-activators MAML2 and MAML3 (Brabletz
et al., 2011). Besides ZEB1 activity, at least two other mech-
anisms have been described that regulate miR-200 expression
in mammary cells. The tumor suppressor p53 can regulate the
expression of miR-200c, and the acquisition of EMT and SC
properties, by directly binding and transactivating the miR-200c/-
141 locus in human normal mammary epithelial cells (Chang
et al., 2011). Alternatively, the regulation of miR-200 clusters
can be achieved epigenetically, by H3K27me3 histone modiﬁca-
tion at the miR-200b-a-429 locus (associated with gene silencing)
induced upon autocrine TGF-β signaling (Lim et al., 2013), or
by CpG hypermethylation of promoter regions (Gregory et al.,
2011).
lncRNA-ATB AND EMT UPON TGF-β STIMULATION
The EMT program activated by TGF-β stimulation also involves
a lncRNA, named lncRNA–ATB (Activated by TGF-β). This cyto-
plasmic lncRNA has been identiﬁed among a group of 100s of
ncRNAs that are regulated upon TGF-β stimulation in hepato-
cellular carcinomas, breast and colorectal cancer cell lines (Yuan
et al., 2014). Bioinformatics predicted that lncRNA–ATB could act
as a competing endogenous RNA for the miR-200 family, due to
three putative binding regions for miR-200 (Yuan et al., 2014).
Indeed, when expressed in cells, lncRNA–ATB phenocopies the
pro-metastatic role of TGF-β by inducing EMT and metastatic
colonization. Mechanistically, this occurs through the positive
modulation of the miR-200 targets, ZEB1 and ZEB2, via com-
petition of lncRNA–ATB over miRNA-200(s). In hepatocellular
carcinomas, high levels of lncRNA–ATB are predictive of poor
survival and distant metastasis. Of note, while the EMT induction
by lncRNA–ATB, and the early phase of tumor dissemination,
could be fully rescued by miR-200 overexpression, the late
metastatic colonization of lung and liver is miR-200-independent
and mediated by the stabilization of IL-11 mRNA (directly bound
by lncRNA–ATB), which in turn activates STAT3 signaling (Yuan
et al., 2014). Hence, lncRNA–ATB drives EMT and metasta-
sis by two independent mechanisms that impinge on different
signaling modules that control CSC-traits (ZEB/miR-200s and
IL-11/STAT3).
miR-22 AND TET-FAMILY DEPENDENT CHROMATIN REMODELING
miR-22 provides yet another regulatory module of miR-200 levels
in mammary cells. This miRNA acts as an epigenetic regulator of
EMT, stemness, andmetastasis in estrogen receptor positive (ER+)
breast cancers through the regulation of hypermethylation of the
miR-200 promoter (Song et al., 2013). miR-22,which has been also
found to be highly expressed in murine progenitor mammary cells
(Ibarra et al., 2007), is upregulated in non-triple-negative breast
cancers, positively correlating with high tumor grade and poor
clinical outcome (Buffa et al., 2011; Enerly et al., 2011; Gregory
et al., 2011; Song et al., 2013). When overexpressed in human or
mouse mammary cells, miR-22 induces a transcriptional repro-
gramming, with upregulation of ZEB1/2 and downregulation of
themiR-200 family, resulting in amesenchymal phenotype, expan-
sion of the MaSC pool, tumorigenesis and metastasis (Song et al.,
2013). Mechanistically, these phenotypes are dependent on the
methylation status of the miR-200 promoter and on the regula-
tion of the TET (10 eleven translocation) family enzymes. These
enzymes (TET1, TET2, and TET3) can modify DNA by remov-
ing the repressive 5-methylcytosine mark (5mC) by hydroxylation
and are all targeted by miR-22 (Tahiliani et al., 2009; Ito et al.,
2010).
THE miR-205/ZEB CIRCUIT AND linc-RoR
miR-205 was identiﬁed as the most abundantly expressed miRNA
in progenitor cells of the mammary gland, puriﬁed using ALDH
as marker (Ibarra et al., 2007), suggesting a role for this miRNA
in lineage speciﬁcation and mammary gland formation. miR-205
is frequently downregulated in breast cancers and is associated
with tumor relapse in patients with the triple negative subtype,
which typically possess high CSC content (Sempere et al., 2007;
Wang et al., 2013c). miR-205 is involved in the regulation of EMT
through the targeting of ZEB1 (one conserved site) and ZEB2
(two conserved sites) and acts cooperatively with miRNAs of the
miR-200 family in the speciﬁcation of epithelial vs. mesenchymal
fate (Gregory et al., 2008). A novel circuitry, which integrates sig-
naling from the microenvironment with the induction of EMT
has recently been described in breast cancer (Chao et al., 2014).
In this case, the repression of miR-205 is achieved by the activa-
tion of Notch, mediated by the release of the ligand JAG1 by the
tumor stroma, and the binding of theHES1 transcriptional repres-
sor (an effector of the Notch pathway) directly to the miR-205
promoter. Loss of miR-205 increases ZEB1/2 levels and those of
another target, NOTCH2, generating a feedback loop that controls
epithelial polarization (by LLGL1 and LLGL2 genes), symmet-
ric cell division, EMT, and mammary tumorigenesis (Chao et al.,
2014).
This complex circuitry also involves the activity of at least
another regulatory RNA, linc-RoR, a lncRNA involved in pluripo-
tency and embryonic SCs (Loewer et al., 2010). Linc-RoR was
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found to be upregulated in breast tumor samples and was able
to induce EMT in human immortalized mammary epithelial
cells (MCF10A). The function of linc-RoR in the maintenance
of induced pluripotent stem cells (iPSCs) and self-renewal of
embryonic stem cells (ES cells) has been linked to its cytosolic
localization and its ability to function as a competing endogenous
RNA for tumor suppressivemiRNAs (such asmiR-145;Wang et al.,
2013b). Similarly, in the breast compartment, linc-RoR interacts
with endogenous miR-205 and induces the derepression of ZEB2,
fostering the EMT program and the acquisition of SC traits by
cancer cells (Hou et al., 2014).
HOTAIR AND PRC2
HOX antisense intergenic RNA is a lncRNA generated by anti-
sense transcription of the HOXC gene cluster (Rinn et al., 2007).
The primary function of HOTAIR is during embryonic devel-
opment, when it regulates the silencing of the distant HOXD
locus (transregulation), acting as a scaffold and bringing two
different chromatin remodeling complexes to the same locus to
enforce gene silencing (Rinn et al., 2007). This recruitment of
chromatin remodelers is mediated by two different RNA domains
in HOTAIR: (i) one comprising the ﬁrst 300 nts of HOTAIR,
which physically associate with the PRC2 complex via EZH2 to
induceH3K27me3; and (ii) the other comprising the last 700 nts of
HOTAIR,which bind to the LSD1-coREST complex that demethy-
lates H3K4me2, hence reinforcing transcriptional repression (Tsai
et al., 2010).
HOX antisense intergenic RNA is also frequently upregu-
lated in breast cancer metastasis, and its expression in primary
tumors is a predictor of invasiveness and adverse outcome, par-
ticularly in ER-positive cancers (Gupta et al., 2010; Gutschner
and Diederichs, 2012). The overexpression of HOTAIR is sufﬁ-
cient to promote invasion and metastasis of breast cancer cells
by re-directing the activity of the PRC2 complex to hundreds
of genes, including many metastasis suppressor genes (Gupta
et al., 2010). Accordingly, HOTAIR silencing inhibits metastasis,
especially in cells with high PRC2 activity (Gupta et al., 2010).
Intriguingly, the Breast Cancer 1, early onset gene (BRCA1),
whose mutations are responsible for a number of inherited breast
cancers, inhibits the interaction between PRC2 and HOTAIR
by competing with HOTAIR for binding to EZH2. This obser-
vation suggests that BRCA1 loss could induce tumorigenesis
also by an EZH2/HOTAIR-dependent mechanism (Wang et al.,
2013a).
Elevated levels of HOTAIR are predictive of unfavorable prog-
nosis in other cancers (such as colon and liver) pointing to a more
general role in oncogenesis (Kogo et al., 2011; Yang et al., 2011).
Indeed, EMT induced by TGF-β treatment in colon (DLD-1/HT-
29) and mammary (MCF10A) cell lines was shown to involve and
be dependent on HOTAIR expression (Pádua Alves et al., 2013).
Finally, since HOTAIR regulates the HOXD locus, it has
been suggested that this lncRNA downregulates another miRNA
associated with EMT, miR-7, which is dependent on HoxD10
(Reddy et al., 2008). Indeed, miR-7 modulates the histone methyl
transferase SETDB1, regulating a STAT3-dependent EMT, and
acquisitionof SC traits inCD44+ cells derived fromMDA-MB-231
human breast cancer cells (Zhang et al., 2014).
CONCLUDING REMARKS
By sitting at the intersection of complex circuitries that integrate
transcriptional, post-transcriptional, and epigenetic control, ncR-
NAs exert a pervasive function on cell regulation. We are only
starting to appreciate the relevance of this new layer of organiza-
tion in the cellular ‘master plan,’ and the impact of its subversion in
diseases. Indeed, deciphering the role of ncRNAs in cancer is espe-
cially desirable, not only from the perspective of understanding the
molecular basis of this disease, but also with the view of develop-
ing novel clinical tools and treatments. With this outlook in mind,
a number of important cultural and technological challenges lay
ahead of us.
First, a true understanding of the functions of ncRNAs can
be obtained only at the systems level. This seems to be necessi-
tated by the very nature of the workings of this class of regulators,
which act on multiple targets and are integrated in multiple cel-
lular molecular functions, thus, affecting phenotypes in complex
ways. Simply put, the reductionistic approach (even when sophis-
ticated) that has served us reasonably well in deciphering gene
function is bound to produce limited knowledge on the biology
of ncRNAs. We will have to devise strategies that contemplate the
integration of multiple omics approaches, including transcrip-
tomics, proteomics, and epigenomics, in addition to phenotypical
analysis, to understand the impact of the experimental modula-
tion of the levels of ncRNAs. And yet, high throughput analysis will
not sufﬁce. High-resolution studies will also be needed, including
quantitative assessment, analysis of threshold levels of action, res-
olution of the signals in space and time, dependency on cellular
context and developmental stage.
In the particular case of lncRNAs, a series of additional limita-
tions will have to be overcome. A major challenge will be to obtain
the complete annotation of tissue-speciﬁc and/or cell type-speciﬁc
lncRNAs, a task that might require years. More importantly, we
will need to deﬁne genetic models to study their functions. This
represents a formidable task: the genomic loci of lncRNAs are fre-
quently located in gene-rich areas, often overlapping with other
genetic units, which renders traditional knock-out or knock-in
strategies less than ideal. Moreover, the fact that lncRNAs fre-
quently exert positional effects in cis further complicates their
analysis.
However, the ﬁeld of applications for ncRNAs, especially in
cancer, harbors great promise. The expression of ncRNAs, espe-
cially lncRNAs, is tightly and speciﬁcally regulated in time and
as a function of the cellular context. This property makes them
appealing diagnostic markers, since they can distinguish between
cell types in the same tissue and between different functional
states of the same lineage (for instance, cells poised for EMT).
Their application as markers, for diagnostic/prognostic assess-
ment and for therapy stratiﬁcation seems, therefore, a reasonable
perspective.
The ultimate goal, obviously, would be to exploit ncRNAs
as therapeutic tools. The evidence, herein reviewed, that these
molecules have a key role in cell fate determination and in the
modulation of cellular plasticity, leading to the acquisition of
stem-related properties, support such a possibility. One impor-
tant advantage of ncRNA-based therapies would be the wide range
of intracellular targets, which should minimize the possibility of
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escape (drug resistance) due to the acquisition of secondary muta-
tions by cancer cells. One of the major hurdles, on the other hand,
resides in the lack of suitable (and speciﬁc) vectors for delivery,
a problem shared with all forms of gene therapy in cancer. How-
ever, ncRNAsmight possess an intrinsic and exploitable advantage.
Given their multi-target characteristics, the action of ncRNAs
might be, at least in some cases, cell-context dependent. In other
words, the modulation of ncRNA levels might not lead to stereo-
typical consequences in all cell types, but to (more or less) speciﬁc
ones, as a function of the cell type. If so, the need for speciﬁc
delivery might be alleviated, at least in part, if the “right” ncRNA
can be selected to exert the desired effect only in the desired cell
types. Clearly, a deeper understanding of the biological effects of
the various ncRNAs will need to be acquired before this possibility
can be actualized into real therapeutic strategies.
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